HAVRIX JUNIOR 720 INACTIVATED HEPATITIS VACCINE AED ADSORBED injection suspension medication leaflet

J07BC02 inactivated hepatitis A vaccine • Antiinfectives for systemic use | Viral vaccines | Hepatitis vaccines

The inactivated hepatitis A vaccine is used to prevent infection with the hepatitis A virus (HAV), which can cause acute hepatitis, an inflammatory liver disease. The vaccine contains inactivated hepatitis A viruses, which stimulate the immune system to produce specific antibodies against HAV.

The vaccine is administered intramuscularly, usually in two doses, 6-12 months apart. It is recommended for individuals traveling to endemic areas, children, food industry workers, and others at increased risk of infection.

Common side effects include pain at the injection site, mild fever, fatigue, and nausea. In rare cases, severe allergic reactions may occur.

The inactivated hepatitis A vaccine is an important preventive measure for reducing the risk of HAV infection and its associated complications, contributing to public health protection.

General data about HAVRIX JUNIOR 720 INACTIVATED HEPATITIS VACCINE AED ADSORBED

Substance: inactivated hepatitis A vaccine

Date of last drug list: 01-07-2013

Commercial code: W57776002

Pharmaceutical form: injection suspension

Packing volume: 0,5ml

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GLAXOSMITHKLINE BIOLOGICALS S.A. - BELGIA

Holder: GLAXOSMITHKLINE BIOLOGICALS S.A. - BELGIA

Number: 3696/2011/02

Shelf life: 3 years

Concentrations available for inactivated hepatitis A vaccine

1440 U.El./ml, 160 U ANTIGENICE, 25 U/0.5ml, 50 U/ml, 720 U. Elisa

Other substances similar to inactivated hepatitis A vaccine